JP2018528229A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528229A5
JP2018528229A5 JP2018515059A JP2018515059A JP2018528229A5 JP 2018528229 A5 JP2018528229 A5 JP 2018528229A5 JP 2018515059 A JP2018515059 A JP 2018515059A JP 2018515059 A JP2018515059 A JP 2018515059A JP 2018528229 A5 JP2018528229 A5 JP 2018528229A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
salt
heterocyclyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018515059A
Other languages
English (en)
Japanese (ja)
Other versions
JP6795588B2 (ja
JP2018528229A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/072216 external-priority patent/WO2017050714A1/en
Publication of JP2018528229A publication Critical patent/JP2018528229A/ja
Publication of JP2018528229A5 publication Critical patent/JP2018528229A5/ja
Application granted granted Critical
Publication of JP6795588B2 publication Critical patent/JP6795588B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018515059A 2015-09-22 2016-09-20 ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド Expired - Fee Related JP6795588B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562221649P 2015-09-22 2015-09-22
US62/221,649 2015-09-22
PCT/EP2016/072216 WO2017050714A1 (en) 2015-09-22 2016-09-20 Pyridinone dicarboxamide for use as bromodomain inhibitors

Publications (3)

Publication Number Publication Date
JP2018528229A JP2018528229A (ja) 2018-09-27
JP2018528229A5 true JP2018528229A5 (enExample) 2019-10-17
JP6795588B2 JP6795588B2 (ja) 2020-12-02

Family

ID=56943545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515059A Expired - Fee Related JP6795588B2 (ja) 2015-09-22 2016-09-20 ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド

Country Status (9)

Country Link
US (1) US10370356B2 (enExample)
EP (1) EP3353162A1 (enExample)
JP (1) JP6795588B2 (enExample)
KR (1) KR20180052762A (enExample)
CN (1) CN108137541B (enExample)
AU (1) AU2016326864A1 (enExample)
CA (1) CA2998545A1 (enExample)
RU (1) RU2018112312A (enExample)
WO (1) WO2017050714A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190006567A (ko) 2016-05-24 2019-01-18 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 브로모도메인 억제제로서의 피리딘 디카르복사미드 유도체
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. アデノシンアンタゴニストとしてのヘテロ環式化合物
GB201716392D0 (en) * 2017-10-06 2017-11-22 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds
GB201716369D0 (en) * 2017-10-06 2017-11-22 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds
EP4389277A3 (en) * 2017-10-18 2024-10-09 Biotage AB Sample clean up device and method of using it
GB201814167D0 (en) 2018-08-31 2018-10-17 Glaxosmithkline Ip No 2 Ltd Compounds
EP3873474A4 (en) 2018-10-30 2022-07-13 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS USED AS BET INHIBITORS
WO2020150674A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP7465945B2 (ja) 2019-07-02 2024-04-11 ニューベイション・バイオ・インコーポレイテッド Bet阻害剤としてのヘテロ環式化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE60139506D1 (de) 2000-12-28 2009-09-17 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
WO2003070277A1 (en) * 2002-02-19 2003-08-28 Shionogi & Co., Ltd. Antipruritics
GB0211759D0 (en) 2002-05-22 2002-07-03 Glaxo Group Ltd Novel compounds
CA2542007C (en) 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
EP1433788A1 (en) 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor Xa inhibitors
BRPI0416128B8 (pt) 2003-11-03 2021-06-22 Glaxo Group Ltd dispositivo de dispensação de fluido
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
AU2013341200A1 (en) 2012-11-08 2015-07-02 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
CN105189461B (zh) 2013-03-14 2018-05-15 葛兰素史克知识产权第二有限公司 2,3-二取代的1-酰基-4-氨基-1,2,3,4-四氢喹啉衍生物和它们作为溴结构域抑制剂的用途
WO2015011252A1 (en) 2013-07-26 2015-01-29 F. Hoffmann-La Roche Ag Pyrimidine-pyridinone serine/threonine kinase inhibitors
CA2919948C (en) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
MA43940A (fr) 2015-09-02 2018-12-12 Glaxosmithkline Ip No 2 Ltd Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine
BR112018006545A2 (pt) 2015-10-05 2018-10-16 Glaxosmithkline Ip No 2 Ltd ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
ES2840848T3 (es) 2016-04-07 2021-07-07 Glaxosmithkline Ip No 2 Ltd Derivados de piridilo como inhibidores de bromodominio
KR20190006567A (ko) 2016-05-24 2019-01-18 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 브로모도메인 억제제로서의 피리딘 디카르복사미드 유도체

Similar Documents

Publication Publication Date Title
RU2018112312A (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
JP2018529737A5 (enExample)
JP2013510124A5 (enExample)
JP2014511891A5 (enExample)
RU2018142988A (ru) Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена
JP2017525737A5 (enExample)
JP2014129360A5 (enExample)
JP2016518434A5 (enExample)
JP2019502763A5 (enExample)
JP2015504081A5 (enExample)
JP2014507455A5 (enExample)
JP2017521457A5 (enExample)
JP2013527243A5 (enExample)
RU2016137181A (ru) Противофиброзные пиридиноны
RU2016150486A (ru) Ингибиторы бета-лактамазы
JP2014511893A5 (enExample)
RU2013121788A (ru) Ингибиторы репликации вич
JP2013519675A5 (enExample)
RU2017134551A (ru) Новые дигидропиридоизохинолиноны и их фармацевтические композиции для лечения воспалительных расстройств
JP2015516427A5 (enExample)
JP2013209405A5 (enExample)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2019516761A5 (enExample)
JP2017517565A5 (enExample)
JP2020511536A5 (enExample)